Literature DB >> 2646336

Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.

D E Rowe1, R J Carroll, C L Day.   

Abstract

We reviewed all studies (since 1947) reporting recurrence rates for treatment of primary (previously untreated) basal cell carcinomas using surgical excision, radiotherapy, cryotherapy, curettage and electrodesiccation, and Mohs micrographic surgery. Our findings indicate that recurrences following treatment of primary basal cell carcinoma appear later than is generally acknowledged in the literature. We found that less than one-third of all recurrences appear in the first year following treatment; only 50% appear within the first 2 years following treatment; and only 66%, or nearly two-thirds, appear within the first 3 years following treatment. A good rule of thumb is that the 10-year recurrence rate is double, or 2 times, that of the 2-year recurrence rate. Furthermore, 18% of recurrences appear between the fifth and tenth year following treatment. These results held true, irrespective of treatment modality examined. Seventy-two studies reporting short-term recurrence rates (follow-up less than 5 years) had a weighted average recurrence rate of 4.2%, whereas 34 long-term studies (follow-up of 5 years) had a weighted average recurrence rate of 8.7%, or more than 2 times the short-term rate. Five-year recurrence rates by treatment modality are as follows: Mohs micrographic surgery 1.0%, surgical excision 10.1%, curettage and electrodesiccation 7.7%, radiation therapy 8.7%, and cryosurgery 7.5%. We conclude that the reporting of recurrence rate data for basal cell carcinoma should be standardized using 5-year life table analysis, and even more important is our conclusion that lifetime follow-up is necessary after treatment of primary basal cell carcinoma in order both recurrences and new primaries.

Entities:  

Mesh:

Year:  1989        PMID: 2646336     DOI: 10.1111/j.1524-4725.1989.tb03166.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  71 in total

Review 1.  Basal cell carcinoma.

Authors:  C S M Wong; R C Strange; J T Lear
Journal:  BMJ       Date:  2003-10-04

2.  Management of cutaneous tumors with mohs micrographic surgery.

Authors:  Krisinda C Dim-Jamora; Jennifer B Perone
Journal:  Semin Plast Surg       Date:  2008-11       Impact factor: 2.314

3.  The optimal follow-up time for a basal cell carcinoma of the eyelid.

Authors:  J W Tijl; L Koornneff
Journal:  Doc Ophthalmol       Date:  1990-10       Impact factor: 2.379

4.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

Review 5.  [Cryosurgery in dermatology].

Authors:  C C Zouboulis
Journal:  Hautarzt       Date:  2015-11       Impact factor: 0.751

6.  Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Authors:  Melody J Eide; Martin A Weinstock; Raymond G Dufresne; Suleka Neelagaru; Patricia Risica; Gary J Burkholder; David Upegui; Katharine A Phillips; Bruce K Armstrong; Leslie Robinson-Bostom
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

7.  More on Mohs'.

Authors:  H K Steinman
Journal:  West J Med       Date:  1990-12

Review 8.  Skin growths in the aged. Treatment considerations.

Authors:  W Frank; G S Rogers
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 9.  [Basal cell carcinoma and rare form variants].

Authors:  J Liersch; J Schaller
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

10.  Mohs micrographic surgery for periocular skin tumours in Ireland.

Authors:  M P Treacy; N C Wynne; J L Gale; E Duignan; B Moran; A M Flynn; P Ormond; R Barry; R Khan; P Moriarty; L Cassidy
Journal:  Ir J Med Sci       Date:  2015-07-11       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.